Is NCT06940297 recruiting in Rochester, MN?

Yes, NCT06940297 is currently recruiting participants at its Rochester, MN location. This recurrent multiple myeloma clinical trial is actively enrolling qualified participants.

How do I join the recurrent multiple myeloma clinical trial in Rochester?

To join this clinical trial in Rochester, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Rochester clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Recurrent Multiple Myeloma Clinical Trial in Rochester, MN

About This Recurrent Multiple Myeloma Study in Rochester

This phase II trial tests how well giving dasatinib and quercetin with cyclophosphamide, fludarabine and chimeric antigen receptor (CAR)-T cell therapy works in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Dasatinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Quercetin is a compound found in plants that may prevent multiple myeloma from forming. Chemotherapy such as cyclophosphamide and fludarabine are given to help kill any remaining cancer cells in the body and to prepare the bone marrow for CAR-T therapy. Chimeric antigen receptor T-cell Therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Giving dasatinib and quercetin with cyclophosphamide, fludarabine and CAR-T cell therapy may kill more cancer cells in patients with relapsed or refractory multiple myeloma.

Sponsor: Mayo Clinic

Who Can Participate

Inclusion Criteria

Age ≥ 18 years

Relapsed or refractory multiple myeloma who has had at least 3 prior lines of therapies including a proteasome inhibitor, immunomodulatory drug (IMiD) and anti-CD38 monoclonal antibody (mAb)

Ciltacabtagene autoleucel (Carvykti) available for patient

Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2

Life expectancy ≥ 12 weeks

Hemoglobin ≥ 8.0 g/dL (obtained ≤ 14 days prior to registration)

Absolute neutrophil count (ANC) ≥ 1,000/mm\^3 (obtained ≤ 14 days prior to registration)

Platelet count ≥ 50,000/mm\^3 (obtained ≤ 14 days prior to registration)

Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (obtained ≤ 14 days prior to registration)

Note: Patients with Gilbert's syndrome must have a total bilirubin of ≤ 3 x ULN (obtained ≤ 14 days prior to registration)

Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 2 x ULN (obtained ≤ 14 days prior to registration)

Alkaline phosphatase ≤ 1.5 x ULN (obtained ≤ 14 days prior to registration)

Calculated creatinine clearance ≥ 30 ml/min using the Cockcroft-Gault formula (obtained ≤ 14 days prior to registration)

Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only

Note: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required

Sexually active patients and their partners must use an effective method of contraception associated with a low failure rate prior to study entry and for the duration of study participation and for at least 30 days after the last dose of study drug

Provide written informed consent

Willingness to provide mandatory blood and bone marrow specimens for correlative research

Willingness to provide mandatory bone marrow cores and/or tissue specimens for correlative research

Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)

Exclusion Criteria

Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or AL amyloidosis

Failure to recover from acute, reversible effects of prior therapy regardless of interval since last treatment.

EXCEPTION: Grade 1 peripheral (sensory) neuropathy that has been stable for at least 1 month since completion of prior treatment

Any of the following because this study involves an agent that has known genotoxic, mutagenic, and teratogenic effects:

Pregnant persons

Nursing persons

Persons of childbearing potential (and persons able to father a child) who are unwilling to employ adequate contraception

Major surgery ≤ 28 days prior to registration

Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens

Immunocompromised patients and patients known to be HIV positive.

NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, or those currently receiving antiretroviral therapy with good control of HIV, are eligible for this trial

Evidence of cardiovascular disease risk, as defined by any of the following:

Evidence of current clinically significant uncontrolled arrhythmias, including clinically significant ECG abnormalities such as 2nd degree (Mobitz Type II) or 3rd degree atrioventricular (AV) block

History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within three (3) months of screening.

Class III or IV heart failure as defined by the New York Heart Association functional classification system

Uncontrolled hypertension

History of life-threatening ventricular arrhythmias

QTC interval \[electrocardiogram (ECG)\] ≥ 450 msec

Uncontrolled intercurrent illness including, but not limited to:

Ongoing or active infection

Any medical condition that would make participation unduly hazardous

Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm

Live vaccine ≤ 6 weeks prior to registration

Has taken a strong inhibitor or inducer of CYP3A4/5, including grapefruit, St. John's Wort or related products ≤ 14 days prior to registration.

Note: If required, patients may receive a short course of strong inhibitors or inducers for treatment of symptoms, but dasatinib dose must be adjusted as indicated

Known hypersensitivity or allergy to dasatinib or quercetin

Patients on therapeutic doses of anticoagulants (e.g. warfarin, heparin, low molecular weight heparin, factor Xa inhibitors, etc).

On antiplatelet agents (e.g. full dose aspirin, clopidogrel etc.)

NOTE: Baby aspirin, if necessary for cardioprotection, will be allowed

On quinolone antibiotic therapy for treatment or for prevention of infections products ≤10 days prior to registration

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Rochester?

Yes, this clinical trial (NCT06940297) has an active research site in Rochester, MN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Recurrent Multiple Myeloma Treatment Options in Rochester, MN

If you're searching for recurrent multiple myeloma treatment options in Rochester, MN, this clinical trial (NCT06940297) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Rochester research site is actively enrolling participants for this clinical trial. You'll receive care from experienced recurrent multiple myeloma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all recurrent multiple myeloma clinical trials near you to find additional studies recruiting in your area.

Recurrent Multiple Myeloma Clinical Trial in Rochester, MN

Expert Care in Rochester

IRB Approved

No-Cost Care

Apply for This Rochester Location

Why Participate?

Simple Process